caa a22 4500 469049154 CHVBK 20180323132825.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF00174118 doi (NATIONALLICENCE)springer-10.1007/BF00174118 Hyaluronan (hyaluronic acid) in lung lavage of asbestos-exposed humans and sheep [Elektronische Daten] [André Cantin, Pierre Larivée, Marc Martel, Raymond Bégin] The concentration of hyaluronan was measured in the bronchoalveolar lavage fluid (BALF) of 18 control subjects and 27 workers from the asbestos mills and mines of Québec, 9 without asbestosis and 18 with asbestosis. Hyaluronan was also measured in the BALF of 9 control sheep exposed to 100 ml phosphate-buffered saline (PBS) at 10 day intervals for 39 months, and 13 sheep exposed at the same intervals to 100 mg chrysotile in 100 ml PBS for 24 months. At month 24, the asbestos-exposed sheep were classified into 3 groups: (A) 4 sheep exposed to PBS alone, (B) 4 sheep exposed to 10 mg chrysotile asbestos every 10 days, and (C) 5 sheep exposed to 100 mg chrysotile asbestos every 10 days for 15 months. The BALF hyaluronan averaged 53.9 ± 7.4 ng/ml in human controls, 67.5 ± 10.3 ng/ml in asbestos-exposed workers without asbestosis, and 206 ± 83 ng/ml in workers with asbestosis (p < 0.05 vs. normal). In the control sheep, BALF hyaluronan was 34.7 ± 6.9 ng/ml, and it was 31.5 ± 17.8 ng/ml in the low-dosage asbestos-exposed group (A), 83.0 ± 27.7 ng/ml in the intermediate-dose group (B), and 248.0 ± 134.7 ng/ml in the high-dosage group (C) (p < 0.05 vs. controls). In contrast, the release of plasminogen activator, a protease that may play a role in limiting the fibrotic process, was increased in group A, but not in groups B and C. In conclusion, BALF hyaluronan constitutes an indicator of lung interstitial tissue changes that may reflect the activity of the fibrosing alveolitis associated with chronic asbestos exposure. Springer-Verlag, 1992 Interstitial fibrosis nationallicence Proteoglycans nationallicence Alveolitis nationallicence Lung matrix nationallicence Plasminogen activator nationallicence Cantin André Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut Larivée Pierre Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut Martel Marc Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut Bégin Raymond Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut Lung Springer-Verlag 170/4(1992-07-01), 211-220 0341-2040 170:4<211 1992 170 408 https://doi.org/10.1007/BF00174118 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00174118 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Cantin André Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut NATIONALLICENCE 700 1- Larivée Pierre Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut NATIONALLICENCE 700 1- Martel Marc Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut NATIONALLICENCE 700 1- Bégin Raymond Unité de Recherche Pulmonaire, Centre Hospitalier Universitaire de Sherbrooke, 12e Ave Nord, 3001, Sherbrooke, (Qc), Canada aut NATIONALLICENCE 773 0- Lung Springer-Verlag 170/4(1992-07-01), 211-220 0341-2040 170:4<211 1992 170 408 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer